E-Posters-10235_Gruenenfelder

10235_Gruenenfelder

Pdf Summary

This study focused on the early and consistent improvements in urinary symptoms and quality of life outcomes in female overactive bladder (OAB) patients with urinary incontinence (UI) treated with onabotulinumtoxinA. The study was a randomized, placebo-controlled, multicenter trial with onabotulinumtoxinA 100U. The objective was to assess the earliest time to treatment response and quality of life outcomes. The study enrolled patients who were inadequately managed by an anticholinergic drug and had OAB for at least 6 months. The patients were randomized to receive either onabotulinumtoxinA or placebo.<br /><br />The results showed that as early as week 1, the onabotulinumtoxinA group had significantly greater reductions in UI episodes per day compared to the placebo group. Additionally, a higher proportion of patients in the onabotulinumtoxinA group achieved complete continence (100% reduction in UI episodes) at week 1, which was sustained through week 12. The study also found significant improvements in quality of life as early as week 1, with improvements in the total score of the Incontinence-Quality of Life (I-QOL) questionnaire.<br /><br />The study demonstrated that onabotulinumtoxinA treatment led to significant decreases in UI and other OAB symptoms as well as improvements in quality of life. These improvements continued through week 12. The treatment was well tolerated with no unexpected safety signals. The most common adverse event was urinary tract infection.<br /><br />In conclusion, this study showed that onabotulinumtoxinA treatment in female OAB patients resulted in early and consistent improvements in urinary symptoms and quality of life. The treatment was well tolerated and had a favorable safety profile.

Keywords

study

urinary symptoms

quality of life outcomes

female overactive bladder

urinary incontinence

onabotulinumtoxinA

randomized trial

placebo-controlled

multicenter trial

early treatment response